A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Kodiak Sciences Inc
- Study ID
- NCT04964089
- Phase
- PHASE3
- Status
- Completed
Conditions
- Wet Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- KSI-301 — DRUGIntravitreal Injection
- Aflibercept — DRUGIntravitreal Injection
- Sham Procedure — OTHERThe sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study Details
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
Key Dates
- Start date
- Jun 23, 2021
- Status verified
- Jun 2024
- Primary completion
- Mar 28, 2023
- Completion
- Apr 6, 2023
Study Design
- Enrollment
- 557 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: KSI-301 (Treatment Group A)Intravitreal injection of KSI-301 (5 mg) at Day 1 once every 4 weeks via intravitreal injection through Week 44.
- Active Comparator: Aflibercept (Treatment Group B)Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 3 monthly doses followed by intravitreal injection of aflibercept (2 mg) once every 8 weeks from Week 16 to Week 44. Sham injections will be administered at each monthly visit where an active treatment is not administered.
Primary Outcome Measure
Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. [ Time Frame: Day 1 to Week 48 ]
Locations (65)
Find similar trials in Phoenix, AZ
Related Studies
- MMP-9 Inhibition for Recalcitrant Wet AMDPHASE2 · Recruiting · University of Iowa · Iowa City, Iowa
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDPHASE3 · Recruiting · AbbVie · Phoenix, Arizona